相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Randomized CLIO/BGOG-ov10 trial of olaparib monotherapy versus physician's choice chemotherapy in relapsed ovarian cancer
Adriaan Vanderstichele et al.
GYNECOLOGIC ONCOLOGY (2022)
Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Hyuna Sung et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2021)
Maintenance olaparib for patients with newly diagnosed advanced ovarian cancer and a BRCA mutation (SOLO1/GOG 3004): 5-year follow-up of a randomised, double-blind, placebo-controlled, phase 3 trial
Susana Banerjee et al.
LANCET ONCOLOGY (2021)
Tumors defective in homologous recombination rely on oxidative metabolism: relevance to treatments with PARP inhibitors
Alvaro Lahiguera et al.
EMBO MOLECULAR MEDICINE (2020)
Clinical Implications of DNA Repair Defects in High-Grade Serous Ovarian Carcinomas
Michela Camilla Milanesio et al.
CANCERS (2020)
The Landscape and Therapeutic Implications of Molecular Profiles in Epithelial Ovarian Cancer
Ludivine Dion et al.
JOURNAL OF CLINICAL MEDICINE (2020)
First-Line Management of Advanced High-Grade Serous Ovarian Cancer
Reem D. Mahmood et al.
CURRENT ONCOLOGY REPORTS (2020)
PARP inhibitors in ovarian cancer
Elisena Franzese et al.
CANCER TREATMENT REVIEWS (2019)
Epithelial ovarian cancer
Stephanie Lheureux et al.
LANCET (2019)
Olaparib and α-specific PI3K inhibitor alpelisib for patients with epithelial ovarian cancer: a dose-escalation and dose-expansion phase 1b trial
Panagiotis A. Konstantinopoulos et al.
LANCET ONCOLOGY (2019)
Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial
Kathleen N. Moore et al.
LANCET ONCOLOGY (2019)
Alpelisib for PIK3CA-Mutated, Hormone Receptor-Positive Advanced Breast Cancer
Fabrice Andre et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
A decade of clinical development of PARP inhibitors in perspective
J. Mateo et al.
ANNALS OF ONCOLOGY (2019)
Management of Platinum-Resistant, Relapsed Epithelial Ovarian Cancer and New Drug Perspectives
Eric Pujade-Lauraine et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
A. Gonzalez-Martin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Veliparib with First-Line Chemotherapy and as Maintenance Therapy in Ovarian Cancer
R. L. Coleman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer
I. Ray-Coquard et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Biomarkers of platinum resistance in ovarian cancer: what can we use to improve treatment
Belinda van Zyl et al.
ENDOCRINE-RELATED CANCER (2018)
Synthetic lethal therapies for cancer: what's next after PARP inhibitors?
Alan Ashworth et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2018)
Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
K. Moore et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Fifth Ovarian Cancer Consensus Conference of the Gynecologic Cancer InterGroup: recurrent disease
M. K. Wilson et al.
ANNALS OF ONCOLOGY (2017)
Establishment of Patient-Derived Tumor Xenograft Models of Epithelial Ovarian Cancer for Preclinical Evaluation of Novel Therapeutics
Joyce F. Liu et al.
CLINICAL CANCER RESEARCH (2017)
Epidemiology of ovarian cancer: a review
Brett M. Reid et al.
CANCER BIOLOGY & MEDICINE (2017)
The PI3K Pathway in Human Disease
David A. Fruman et al.
CELL (2017)
Olaparib monotherapy in patients with advanced relapsed ovarian cancer and a germline BRCA1/2 mutation: a multistudy analysis of response rates and safety
U. A. Matulonis et al.
ANNALS OF ONCOLOGY (2016)
Moving beyond the platinum sensitive/resistant paradigm for patients with recurrent ovarian cancer
Ronald D. Alvarez et al.
GYNECOLOGIC ONCOLOGY (2016)
Phosphoinositide 3-kinase inhibitors induce DNA damage through nucleoside depletion
Ashish Juvekar et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2016)
Homologous Recombination Deficiency: Exploiting the Fundamental Vulnerability of Ovarian Cancer
Panagiotis A. Konstantinopoulos et al.
CANCER DISCOVERY (2015)
Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer
David D. Bowtell et al.
NATURE REVIEWS CANCER (2015)
2014 FIGO staging for ovarian, fallopian tube and peritoneal cancer Clinical comment
David G. Mutch et al.
GYNECOLOGIC ONCOLOGY (2014)
Bevacizumab Combined With Chemotherapy for Platinum-Resistant Recurrent Ovarian Cancer: The AURELIA Open-Label Randomized Phase III Trial
Eric Pujade-Lauraine et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial
Shahneen K. Sandhu et al.
LANCET ONCOLOGY (2013)
Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors
Junko Murai et al.
CANCER RESEARCH (2012)
PI3K Inhibition Impairs BRCA1/2 Expression and Sensitizes BRCA-Proficient Triple-Negative Breast Cancer to PARP Inhibition
Yasir H. Ibrahim et al.
CANCER DISCOVERY (2012)
Combining a PI3K Inhibitor with a PARP Inhibitor Provides an Effective Therapy for BRCA1-Related Breast Cancer
Ashish Juvekar et al.
CANCER DISCOVERY (2012)
Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study
Karen A. Gelmon et al.
LANCET ONCOLOGY (2011)
Integrated genomic analyses of ovarian carcinoma
D. Bell et al.
NATURE (2011)
Incorporation of Bevacizumab in the Primary Treatment of Ovarian Cancer
Robert A. Burger et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
A Phase 3 Trial of Bevacizumab in Ovarian Cancer
Timothy J. Perren et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Targeting the phosphoinositide 3-kinase pathway in cancer
Pixu Liu et al.
NATURE REVIEWS DRUG DISCOVERY (2009)
Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer
Stephen A. Cannistra et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Duration of response to second-line, platinum-based chemotherapy for ovarian cancer: Implications for patient management and clinical trial design
M Markman et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
分享论文
